Physician profile
Barbie Johnson
NPI 1396280137
$3,016.67
in general payments reported to CMS, 2019-2025
35 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $499 · 2023: $605 · 2024: $485 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $345.61 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $276.22 | 2022-2025 | |
| Novo Nordisk INC | $265.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $260.91 | 2021-2025 | |
| Lilly USA, LLC | $213.52 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $196.73 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.30 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.99 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $129.31 | 2022 | |
| Abbott Laboratories | $93.77 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $88.10 | 2022 | |
| Pfizer INC. | $76.19 | 2022-2025 | |
| Glaxosmithkline, LLC. | $68.17 | 2022-2024 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $66.67 | 2024-2025 | Voquezna |
| Amgen INC. | $66.38 | 2022-2025 | Evenity, Prolia, Otezla |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.